Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 349

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 349
---
                   |     |              | (70,917,853 | ) |     |               | (43,089,821 | ) |
| Total stockholders’ deficit                                                                           |     |              |  (1,894,563 | ) |     |               | (42,057,695 | ) |
| Total liabilities, convertible preferred stock and stockholders’ deficit                              |     | $            |   6,206,929 |   |     | $             |   5,126,302 |   |

See accompanying notes to the consolidated financial statements Reflects a 1-for-100 reverse stock split effective January 8, 2025 and a 1-for-20 reverse stock split effective June 13, 2025 F-32 CERO THERAPEUTICS HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS

|                                                            |     |            |      For the 
  period from 
 February 14, 
 2024 through 
 December 31, 
         2024 |   |     |              |      For the 
  period from 
   January 1, 
 2024 through 
 February 13, 
         2024 |   |     |              |      For the 
   year ended 
 December 31, 
         2023 |   |
|:-----------------------------------------------------------|:----|:-----------|-------------:|:--|:----|:-------------|-------------:|:--|:----|:-------------|-------------:|:--|
|                                                            |     | -Successor |              |   |     | -Predecessor |              |   |     | -Predecessor |              |   |
| Operating expenses:                                        |     |            |              |   |     |              |              |   |     |              |              |   |
| Research and development                                   |     | $          |    6,315,552 |   |     | $            |      764,192 |   |     | $            |    5,288,580 |   |
| General and administrative                                 |     |            |    8,985,351 |   |     |              |      132,941 |   |     |              |    2,386,469 |   |
| Total operating expenses                                   |     |            |   15,300,903 |   |     |              |      897,133 |   |     |              |    7